Clovis Oncology Announces 2015 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Mizuho Securities Remains Sidelined on Clovis Oncology (CLVS) Ahead of ODAC Panel
February 29, 2016 7:45 AM ESTMizuho Securities reiterated a Neutral rating on Clovis Oncology (NASDAQ: CLVS), and cut the price target to $21.00 (from $23.00), ahead of an ODAC Panel, scheduled for April 12th. Mizuho expects examination of dosing, response rates, patient characteristics and duration of therapy to be key... More
Clovis Oncology (CLVS) Misses Q4 EPS Views
February 25, 2016 4:15 PM ESTClovis Oncology (NASDAQ: CLVS) reported Q4 EPS of ($3.12), $0.68 worse than the analyst estimate of ($2.44).
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
... More